- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07727512
PCOS and Brain Health
Functional and Structural Impacts of Polycystic Ovary Syndrome (PCOS) on Brain Health
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Aim 1: To determine whether individuals with PCOS exhibit reduced CBF at global, lobe and regional brain levels.
Aim 2: To assess whether individuals with PCOS have alterations in brain structure including grey and white volume, cortical thickness, or connectivity compared to controls.
Aim 3: To evaluate whether individuals with PCOS demonstrate impairments in cognitive performance, including verbal fluency, memory, and processing speed, relative to controls.
Aim 4: To characterize systemic immune cell states, circulating inflammatory and metabolic profiles, and epigenomic regulatory landscapes in peripheral blood of individuals with and without PCOS, and to evaluate whether these multiomic signatures are associated with CBF, brain structure, connectivity, and cognitive performance.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Sharon Blohowiak
- Telefoonnummer: (608) 262-5977
- E-mail: sblohowiak@wisc.edu
Studie Locaties
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53792
- Werving
- University of Wisconsin
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria (Participants with PCOS):
Rotterdam criteria demonstrating two out of the three criteria. These are:
- Presence of clinical hyperandrogenism or biochemical hyperandrogenism
- A history of irregular menstrual cycles
- Presence of polycystic ovarian morphology on ultrasound
Inclusion Criteria (Healthy Controls):
- Regular menstrual cycles (not meeting criteria for irregular cycles above)
- No diagnosis of PCOS
- Controls may have isolated hirsutism or polycystic ovaries on ultrasound as long as they do not meet Rotterdam criteria for PCOS
Exclusion Criteria:
- Current pregnancy
- Preexisting diagnosis of type 1 diabetes
- Severe obesity (body mass index (BMI) greater than 45kg/m2)
- Preexisting diagnosis of hypertension requiring antihypertensive medication or blood pressure of greater than 160/100 on two separate occasions during clinical care
- History of neurologic disease or stroke
- History of myocardial infarction or deep venous thrombosis
- Endometriosis confirmed by prior laparoscopy
- Autoimmune conditions including lupus, multiple sclerosis, and active malignancy
- Immuno-modulating medications
Conditions incompatible with MRI scanning, including but not limited to
- Certain implanted metal devices or foreign bodies
- Severe claustrophobia
- Post-menopausal
- Participants will be excluded if they have taken hormonal contraception or fertility medication in the last month
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Participants with PCOS
N=30 participants recruited
|
MRI visit will take approximately 1.5 hour (55-60 minutes in MRI) and will involve structural scans of the brain, and scans at rest and while performing cognitive tasks.
Andere namen:
DEXA scan for obtaining body composition, NIH toolbox to assess cognitive test, and optional graded exercise test (GXT).
|
|
Healthy Controls
N=15 age and BMI-matched participants recruited
|
MRI visit will take approximately 1.5 hour (55-60 minutes in MRI) and will involve structural scans of the brain, and scans at rest and while performing cognitive tasks.
Andere namen:
DEXA scan for obtaining body composition, NIH toolbox to assess cognitive test, and optional graded exercise test (GXT).
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cerebral Blood Flow (CBF) at rest
Tijdsspanne: data collected during a 2-hour MRI visit (anytime up to 3 months on study)
|
Arterial Spin Labeling (ASL) color atlases and 4D Flow MRI will be used to measure CBF at rest.
CBF will be measured in each of six brain regions: temporal, parietal, frontal, occipital, subcortical, and brainstem.
|
data collected during a 2-hour MRI visit (anytime up to 3 months on study)
|
|
Circulating Sex Hormone Levels
Tijdsspanne: data collected during a 2-hour MRI visit (anytime up to 3 months on study)
|
data collected during a 2-hour MRI visit (anytime up to 3 months on study)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Body composition via DEXA scan
Tijdsspanne: data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
Percent body fat and lean mass to be measured via Dual-Energy X-ray Absorptiometry (DEXA) scan.
|
data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
|
NIH Toolbox: Dimensional Change Card Sort Test
Tijdsspanne: data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
NIH Toolbox to assess neurocognitive function.
The Dimensional Change Card Sort Test measures accuracy: the number of accurate responses, up to a maximum of 40.
|
data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
|
NIH Toolbox: Pattern Comparison Processing Speed Test
Tijdsspanne: data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
NIH Toolbox to assess neurocognitive function.
The Pattern Comparison Processing Speed Test measures how many correct responses the participant has within 90 seconds.
There is a maximum of 130 items.
|
data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
|
NIH Toolbox: Flanker Inhibitory Control and Attention
Tijdsspanne: data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
NIH Toolbox to assess neurocognitive function.
The Flanker test is a measure of executive function and is scored using a T-score where 100 is the average, higher scores indicate better performance.
|
data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
|
Cardiorespiratory fitness (VO2max) [Optional]
Tijdsspanne: data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Laura Cooney, MD, University of Wisconsin, Madison
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Endocriene systeemziekten
- Neoplasmata
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Genitale ziekten, vrouw
- Ovariële ziekten
- Adnexale ziekten
- Gonadale aandoeningen
- Ovariële cysten
- Cysten
- Polycysteus ovarium syndroom
- Diagnostische technieken en procedures
- Diagnose
- Tomografie
- Diagnostische beeldvorming
- Magnetische resonantie beeldvorming
Andere studie-ID-nummers
- 2026-0690
- Protocol Version 6/29/2026 (Andere identificatie: UW Madison)
- SMPH / Reproductive Endo (REI) (Andere identificatie: UW Madison)
- ICTR Pilot Award (Ander subsidie-/financieringsnummer: NCATS)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .